As far as survival and efficacy data is concerned, median OS ranged from 13 months of Basturk et al., to 24.5 months of Milione et al. In the former, there was no survival difference between NEC with Ki67 LI <55% (13 months) vs. ≥55% (16 months) [18]. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.